Mosunetuzumab Biosimilar - Research Grade

Human

CD3e + CD20

>1mg/ml

ScFv-His

Bulk Anti-Human CD3 (UCHT-1) Antibody (ICH1002), Bulk Anti-Human CD3 (OKT-3) Antibody (ICH1257), Muromonab Biosimilar - Research Grade (ICH5024), Teplizumab Biosimilar - Research Grade (ICH5101), Foralumab Biosimilar - Research Grade (ICH5156), Otelixizumab Biosimilar - Research Grade (ICH5171), Epcoritamab Biosimilar - Research Grade (ICH5319), Dafsolimab Biosimilar - Research Grade (ICH5460), Emirodatamab Biosimilar - Research Grade (ICH5520), Visilizumab Biosimilar - Research Grade (ICH5982)

https://www.imgt.org/mAb-DB/

ICH3002

P07766

916

RRID:AB_2921631

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of mosunetuzumab, supplied strictly for research use only. Mosunetuzumab is a CD20-directed CD3 T-cell engaging bispecific antibody, and this reagent is built to recapitulate that dual-target binding activity so investigators can study CD20 x CD3 bridging biology without using clinical drug product. It is intended as a research tool for functional and preclinical characterization: as a binding and neutralisation reagent, a bispecific-engager positive control, a benchmarking standard against in-house constructs, and a comparator in T-cell redirection and cytotoxicity assays. It is offered at research grade with low endotoxin (typically less than 1 EU/mg, with an ultra-low option under 0.5 EU/mg) and is available in bulk milligram-to-gram quantities suitable for assay development, screening, and preclinical work. It is not the clinical drug and is not for human or veterinary use. Note the card lists an ScFv-His format, whereas mosunetuzumab is a full-length humanized IgG1 bispecific; confirm the actual construct format before finalizing customer-facing copy. Mosunetuzumab engages two targets. CD20 (MS4A1) is a four-pass transmembrane phosphoprotein expressed on B cells from the pre-B through mature stages but absent on plasma cells and stem cells; it contributes to B-cell activation and calcium flux and is a validated marker across B-cell malignancies such as follicular and diffuse large B-cell lymphoma. CD3 epsilon (CD3E, UniProt P07766) is an invariant signaling subunit of the CD3 complex that assembles with the T-cell receptor and the CD3 gamma, delta, and zeta chains; its cytoplasmic ITAM couples antigen recognition to downstream T-cell activation. A CD20 x CD3 bispecific simultaneously binds CD20 on malignant B cells and CD3 epsilon on T cells, forming an immunological synapse that redirects polyclonal T cells to kill target B cells independently of TCR specificity.

BTCT4465A

Detects human CD3/CD20. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Mosunetuzumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Mosunetuzumab (anti-CD3e + CD20) Biosimilar

Q: Is the Mosunetuzumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Mosunetuzumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Mosunetuzumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Mosunetuzumab that binds human CD3e + CD20.